Regulatory Affairs Blog | Global Regulatory Partners

Committed to your success, from Concept to Approval.


China Expediting the Review and Approval of Drugs to Treat Life Threatening Diseases

Chinese health authority published a list with 48 orphan drugs that qualify for an expedite review process of their registration application. The 48 drugs are used for the treatment or prevention of rare and life-threatening diseases, and have alread…

FDA Waiving the Informed Consent for Minimal Risk Clinical Studies

To date, FDA requires all subjects to provide their informed consent before participating in any clinical trial, except when there are life-threatening situations or emergency research conditions.

On November 2018, FDA proposed a new rule that wil…

FDA New Pilot Program for Medical Device Conformity Assessment Accreditation

By September 20120, the US Food and Drug Administration (FDA) is planning to lanch its pilot program for medical device conformity assessment accreditation, known as the Accreditation Scheme for Conformity Assessment (ASCA).

ASCA Pilot Program goa…

New Program for the Review of Innovative Medical Devices in China

The Chinese National Medical Products Administration (NMPA) has published revised requirements for its innovative medical device review program that will take effect December 1, 2018.

The new NMPA policy, Read more

New FDA Pilot Program for 510(k) "Quik" Review

FDA has launched a new pilot program for a “Quick Review“ of 510(k) of certain medical devices, by using the eSubmitter software to format the submission. The devices that qualify for this quick review, as shown on list below, are moderate risk devic…

CFDA Announced Major Changes to Chinese Medical Device Regulations in favor of Foreign Manufacturers

Japan PMDA Raising Medical Device Registration Fees

[vc_row][vc_column][vc_column_text]On April 1st, 2018, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has raised the registration fees for most medical devices . PMDA fee increase is ranging from 8% to 15% across nine device categories as …

China New Policy Pushing Generics over Brands

FDA is aligning its QSR (21 CFR 820) with ISO 13485:2016

Unique Device Identification (UDI) Systems Expansion in Europe

[vc_row][vc_column][vc_column_text css=".vc_custom_1520225945879"]The implementation of Unique Device Identification (UDI) systems in markets beyond the US is increasing, as the European Commission is planning to publish a guidance document on UDI un…

FDA New Pilot Program for Orphan Designation Requests

[vc_row][vc_column][vc_column_text css=".vc_custom_1520175523966"]For Rare Disease Day, the FDA lunched a new pilot program to streamline orphan designation requests to make it easier for applicants and reviewers. The program also includes a tutorial…

FDA-First Agency to Release a Guidance on 3D Printed Products

[vc_row][vc_column][vc_column_text]To keep up with evolving 3D printing technology and to encourage and support innovation in this field, the FDA has released it first technical guidance for manufacturers using 3D-printed technology for medical produ…

Japan cutting prices of new drugs and off-patent drugs


The Ministry of Health, Labor and Welfare is proposing a considerable cut down in the pricing of both off-patent drugs and expensive innovative treatments, and also set up an annual…

CFDA New Clinical Data Requirements for Foreign medical devices

[vc_row][vc_column][vc_column_text]CFDA has proposed changes to Order 650 that would exempt additional types of Class II and III medical devices and IVDs from clinical trial requirements, and a…

FDA New Guidance on De Novo Classification Process

[vc_row][vc_column][vc_column_text]On October 30, 2017 FDA published a new guidance that describes the process for the submission and review of a De Novo classification request for novel devices, that are automatically classified as Class III devices…

2018 FDA Small-Business Medical Device User Fees


  • The US FDA has published new guidance explaining how companies should apply to qualify for small-business medical device user fees instead of much higher standard fees.
  • Generally, companies m…

FDA NEWS: Priority Review for Generic on the Way

Nanomaterial Submissions on the Rise

CFDA Proposes Draft Lowering Barriers for Foreign Drug Manufacturers

Do We Really Need Regulatory Intelligence?

QMS for Virtual Companies

Reality check on 505(b)(2) NDA Approval Pathway

Learn more about how we can assist you with Regulatory, Clinical and Compliance services in your country of interest

GRP provides Regulatory, Clinical and Compliance services across the globe

North America
Latin America
European Union

Choose the Country